Project Grant R43TR005330
Award Date
7/1/25
Completion Date
6/30/26
Dollars Obligated
$350K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This Project Grant award of $450,000 from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) supports the development of biosensors to quantify the genetic payload of viral vectors used in gene therapy. The project aims to create a novel biosensing technology that can differentiate between functional viral vectors and defective particles. This involves studying ligand interactions with full and empty viruses, integrating the ligands with electrochemical biosensors, and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award for $275,000 will support the development of a plasmonic nanopore sensor device for quality control of adeno-associated viruses (AAVs) used in gene therapy. The proposed device will enable accurate characterization of AAV payload (single-stranded DNA, double-stranded DNA, or empty) at low, pre-scale-up concentrations to optimize formulations. The project aims to demonstrate the...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training (CFDA 93.859) program, provides $1,640,169 to Synvivia, Inc. to validate a platform for identifying cyclic peptides that can dramatically increase the yield and quality of adeno-associated virus (AAV) vectors manufactured for gene therapy. The key objectives are to: 1) demonstrate that Synvivia's cyclic peptide discovery library contains peptides that...
The National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, has awarded a $331,034 Project Grant to Vector Surgical LLC to develop the Gene Therapy Catheter (GTC) - an electrical pulsing device designed to enhance the delivery of adeno-associated virus (AAV) gene therapy to the liver. The GTC aims to improve the efficiency and safety of liver-directed gene therapies by combining local delivery with electrical pulsing and a double-balloon system to isolate the...
This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $245,434 to develop a novel hybrid viral vector system for delivering CRISPR gene editing capabilities. The goal is to create a more versatile platform for making multigenic insertions, which could enable treatments for a broader range of conditions beyond just monogenic diseases. The award supports the development of a "chimeric AdAAV" vector that physically...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training (CFDA 93.859) federal grant program, provides $1,095,274 to The Research Foundation For The State University Of New York to develop complementary biotherapeutic delivery platforms for enabling gene re-delivery in gene therapy. The project aims to pioneer innovative delivery strategies that can overcome biological barriers and modulate immune responses to...
This Project Grant award of $304,951 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a scalable and cost-effective manufacturing process for extracellular vesicle (EV)-based gene therapy delivery systems at Neucore Bio, Inc. The project aims to address key technical challenges in EV isolation, purification, and cargo loading to enhance the therapeutic efficacy of EV-based gene therapies, particularly...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
This $305,000 Small Business Innovation Research (SBIR) Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) aims to develop a new class of gene therapies delivered more safely, cost-effectively, and at scale for serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes,...